Sangamo Therapeutics Company

Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Technology: Biotechnology, CAR-T therapy, Cell-based gene therapy, Genetics, Pharmaceutical, Stem cell therapy, Stem cells therapy, Therapeutics
Industry: End-to-end Drug Development, Public
Headquarters: Richmond, California, United States
Founded Date: 1995-01-01
Employees Number: 251-500
Funding Status: IPO
Acquisitions Number: 2
Investors Number: 3
Total Funding: 522100000
Estimated Revenue: $10M to $50M
Last Funding Date: 2019-04-03
Last Funding Type: Post-IPO Equity

Visit Website
info@sangamo.com
https://twitter.com/sangamotx
Register and Claim Ownership